Literature DB >> 2791192

Pharmacokinetics of high-dose busulfan in children.

G Vassal1, A Gouyette, O Hartmann, J L Pico, J Lemerle.   

Abstract

The pharmacokinetics of high-dose busulfan given orally at 1 mg/kg every 6 h over 4 days (total dose, 16 mg/kg) in combined chemotherapy followed by autologous bone marrow transplantation was studied in 12 children with a mean age of 7 years (range, 4-14 years). Busulfan levels in biological fluids were measured by a gas chromatographic assay with mass fragmentographic detection, using a deuterated analogue as the internal standard. In a high-dose regimen, busulfan followed one-compartment model kinetics with zero-order absorption. A mean maximal concentration of 803 +/- 228 ng/ml was achieved at 92-255 min after dosing. The mean elimination half-life was 2.33 h, and the mean total clearance was 119 +/- 54 ml/min per m2, with an apparent distribution volume of 27.10 +/- 11.50 l/m2. A mean trough level of 370 ng/ml was found throughout the 4 days of the chemotherapy course. There were no significant variations in pharmacokinetic parameters measured after the first and last doses. Busulfan was monitored in the CSF of nine children at 3.25-7 h after the last dose and was detected in all patients, with a mean CSF-to-plasma concentration ratio of 0.95 (range, 0.5-1.4).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2791192     DOI: 10.1007/bf00257448

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  20 in total

1.  Measurement of busulfan in plasma by high-performance liquid chromatography.

Authors:  W D Henner; E A Furlong; M D Flaherty; T C Shea; W P Peters
Journal:  J Chromatogr       Date:  1987-05-15

2.  Marrow transplantation for thalassemia.

Authors:  K H Lin; K S Lin; S A Feig
Journal:  Bone Marrow Transplant       Date:  1986-12       Impact factor: 5.483

3.  Convulsions due to high-dose busulphan.

Authors:  R E Marcus; J M Goldman
Journal:  Lancet       Date:  1984-12-22       Impact factor: 79.321

4.  Gas chromatographic determination of busulfan in plasma with electron-capture detection.

Authors:  M Hassan; H Ehrsson
Journal:  J Chromatogr       Date:  1983-10-14

5.  Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue.

Authors:  C Lu; H G Braine; H Kaizer; R Saral; P J Tutschka; G W Santos
Journal:  Cancer Treat Rep       Date:  1984-05

6.  Busulfan and total body irradiation as antihematopoietic stem cell agents in the preparation of patients with congenital bone marrow disorders for allogenic bone marrow transplantation.

Authors:  R Parkman; J M Rappeport; S Hellman; J Lipton; B Smith; R Geha; D G Nathan
Journal:  Blood       Date:  1984-10       Impact factor: 22.113

7.  Busulfan kinetics.

Authors:  H Ehrsson; M Hassan; M Ehrnebo; M Beran
Journal:  Clin Pharmacol Ther       Date:  1983-07       Impact factor: 6.875

Review 8.  High-dose chemotherapy. Concepts and strategies.

Authors:  M Odaimi; J Ajani
Journal:  Am J Clin Oncol       Date:  1987-04       Impact factor: 2.339

9.  Determination of busulfan in plasma by GC-MS with selected-ion monitoring.

Authors:  H Ehrsson; M Hassan
Journal:  J Pharm Sci       Date:  1983-10       Impact factor: 3.534

10.  Toxicological review of busulfan (Myleran).

Authors:  J B Bishop; J S Wassom
Journal:  Mutat Res       Date:  1986-07       Impact factor: 2.433

View more
  27 in total

1.  Will high dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma?

Authors:  S Dupuis-Girod; O Hartmann; E Benhamou; F Doz; F Mechinaud; E Bouffet; C Coze; C Kalifa
Journal:  J Neurooncol       Date:  1996-01       Impact factor: 4.130

2.  The effect of hepatic enzyme inducers on busulfan neurotoxicity and myelotoxicity.

Authors:  W E Fitzsimmons; R Ghalie; H Kaizer
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Intravenous busulfan: in the conditioning treatment of pediatric patients prior to hematopoietic stem cell transplantation.

Authors:  Sheridan M Hoy; Katherine A Lyseng-Williamson
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

4.  Porous metal-organic-framework nanoscale carriers as a potential platform for drug delivery and imaging.

Authors:  Patricia Horcajada; Tamim Chalati; Christian Serre; Brigitte Gillet; Catherine Sebrie; Tarek Baati; Jarrod F Eubank; Daniela Heurtaux; Pascal Clayette; Christine Kreuz; Jong-San Chang; Young Kyu Hwang; Veronique Marsaud; Phuong-Nhi Bories; Luc Cynober; Sophie Gil; Gérard Férey; Patrick Couvreur; Ruxandra Gref
Journal:  Nat Mater       Date:  2009-12-13       Impact factor: 43.841

Review 5.  Clinical pharmacology in the adolescent oncology patient.

Authors:  Gareth J Veal; Christine M Hartford; Clinton F Stewart
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

6.  Quantification of busulfan in saliva and plasma in haematopoietic stem cell transplantation in children : validation of liquid chromatography tandem mass spectrometry method.

Authors:  Manfred Rauh; Daniel Stachel; Michaela Kuhlen; Michael Gröschl; Wolfgang Holter; Wolfgang Rascher
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

7.  Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology.

Authors:  M Hassan; G Oberg; A N Bekassy; J Aschan; H Ehrsson; P Ljungman; G Lönnerholm; B Smedmyr; A Taube; I Wallin
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

8.  Gas-chromatographic analysis of busulfan for therapeutic drug monitoring.

Authors:  L Embree; R B Burns; J R Heggie; G L Phillips; D E Reece; J J Spinelli; D O Hartley; N J Hudon; J H Goldie
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients.

Authors:  Christa E Nath; John W Earl; Nalini Pati; Katherine Stephen; Peter J Shaw
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

10.  Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation.

Authors:  G Vassal; S Koscielny; D Challine; D Valteau-Couanet; I Boland; A Deroussent; J Lemerle; A Gouyette; O Hartmann
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.